NKT cell costimulation: experimental progress and therapeutic promise
about
CD1d- and MR1-Restricted T Cells in SepsisEnhanced TCR Footprint by a Novel Glycolipid Increases NKT-Dependent Tumor ProtectionAll-trans-retinoic acid and the glycolipid α-galactosylceramide combined reduce breast tumor growth and lung metastasis in a 4T1 murine breast tumor model.Invariant natural killer T cells as sensors and managers of inflammation.The split personality of NKT cells in malignancy, autoimmune and allergic disordersInvariant NKT cells increase drug-induced osteosarcoma cell death.Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response.Dendritic cells and their role in tumor immunosurveillance.The preventive role of type 2 NKT cells in the development of type 1 diabetes.A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.Synthesis, self-assembly, and immunological activity of α-galactose-functionalized dendron-lipid amphiphiles.Editorial: CD1- and MR1-Restricted T Cells in Antimicrobial Immunity.Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.Insights Into Mucosal-Associated Invariant T Cell Biology From Studies of Invariant Natural Killer T Cells.
P2860
Q26796132-0B97282C-5199-4117-BD0E-4FBC2D04A78FQ27679771-8BCEAE01-3ECE-4AF0-BAAB-B0BBCDE0572BQ33769503-3A3094FF-C081-4DF6-80CF-87798CA76564Q34302295-5623A18E-991F-44F4-8617-BE564ADCC627Q35590727-17BE809E-7BCD-488A-A69A-21A5C5A88F54Q36446525-4F9AA1E9-8AAE-4F22-A1F5-6FE1122939B2Q36542800-9FCE5B95-68FC-48BD-83AD-FFAF247A6B2AQ36951719-5AF968F6-0F0B-43F2-A013-4FEA99E2C4ACQ37599845-E8CF939C-2D21-4A7B-AC0A-B2CFFE44B82AQ38021625-F24AB262-FCE2-49AE-8BC8-EE697EE8A193Q38132851-EB7601FE-35BD-4B5D-94FD-433ED9ACC0C2Q38634685-F4446D1D-EA6D-482C-AA76-2BC378602307Q39450014-12AAC799-13E1-41AC-93D6-637C7514F8A0Q40514390-4B7777D9-13B0-46A5-A550-3EA8CECDC9FAQ40860044-D08CA5DC-461F-4447-9C60-87ED1C82FBE6Q52645931-C98BFD81-36F3-4A08-90CB-52A6608F6239Q54967775-262FAC66-1055-4BD7-8E1C-B2E5B842960EQ55717169-B89DB495-9D35-4F7E-A6D9-AA8C8B2B419A
P2860
NKT cell costimulation: experimental progress and therapeutic promise
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
NKT cell costimulation: experimental progress and therapeutic promise
@ast
NKT cell costimulation: experimental progress and therapeutic promise
@en
type
label
NKT cell costimulation: experimental progress and therapeutic promise
@ast
NKT cell costimulation: experimental progress and therapeutic promise
@en
prefLabel
NKT cell costimulation: experimental progress and therapeutic promise
@ast
NKT cell costimulation: experimental progress and therapeutic promise
@en
P2093
P2860
P1476
NKT cell costimulation: experimental progress and therapeutic promise
@en
P2093
Marianne J van den Heuvel
Nitan Garg
S M Mansour Haeryfar
P2860
P356
10.1016/J.MOLMED.2010.10.007
P50
P577
2010-11-17T00:00:00Z